  KT-621 Summary
  Dupilumab-like Activity in a Pill

                KT-621 is the first • In preclinical in vitro and in • Phase  1b AD data showed deep STAT6 degradation in
                                                                       blood and skin, robust reductions in disease-relevant Type
                                       vivo studies, it is equal or
                highly selective,      superior to dupilumab           2 biomarkers, meaningful improvements on clinical
                potent, oral STAT6                                     endpoints and PROs in AD and comorbid asthma and
                degrader in the clinic                                 allergic rhinitis, and a favorable safety profile

     OPPORTUNITY

• Over 140M1 potential patient     • Market (with single digit %   • An oral pill with dupi-like       Potential to access
  impact; only ~1% has access to     penetration) projected to       efficacy can transform the        patients beyond biologics-
  advanced systemic therapies        reach >$27B by 20301            treatment paradigm of Type 2      eligible, across all disease
                                                                     diseases                          severities and ages



  STATUS &                • BROADEN2 Phase 2b AD study ongoing, with data by mid-2027
 UPCOMING
 MILESTONES               • BREADTH Phase 2b asthma trial initiated, with data in late-2027



                                                                                                                                    13
